BTF’s ASH Annual Meeting Review 2023 - Portland

Portland, OR US
January 6, 2023 to January 7, 2023

The BTF’s ASH Annual Meeting Review 2023 - Portland is a CME-accredited, in-person hematology conference featuring leading experts in the field. This conference allows professionals an opportunity to discuss current research and advances in the field of blood disorders and hematologic malignancies with colleagues and key opinion leaders. Expert faculty will place key abstract findings from the 64th American Society of Hematology (ASH) Annual Meeting into clinical context and discuss how the results may change the current standard of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for the patients. 

This activity is planned and implemented by the Binaytara Foundation to educate hematologists/oncologists and others involved in the care of patients with hematologic malignancies and benign hematological disorders about the most important updates from the 64th American Society of Hematology (ASH) Annual Meeting in December 2022. Neither the Binaytara Foundation nor this activity is affiliated with the American Society of Hematology (ASH). 

 

Target Audience

  • Hematologist/Oncologists
  • Oncology Physician Assistants/Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Nurses

Learning Objectives

  • Review data presented at the 64th ASH Annual Meeting (2022) and discuss their application in clinical settings.
  • Choose new therapeutic options for the treatment of blood disorders and hematologic malignancies, understanding appropriate indications, and contraindications to these therapeutic approaches.
  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies.
  • Integrate evolving diagnostic, prognostic, and therapeutic approaches to the management of patients with blood disorders and hematologic malignancies.
  • Apply practical expertise gained from clinical situations emphasizing data-based approaches to patients with blood disorders and hematologic malignancies in community practice.
Course summary
Available credit: 
  • 7.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 7.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 7.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 7.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 7.50 Contact Hours.
Course opens: 
10/01/2022
Course expires: 
02/07/2023
Event starts: 
01/06/2023 - 4:00pm PST
Event ends: 
01/07/2023 - 3:35pm PST
Cost:
$300.00
Add to calendar: 

Conference Chair: Dr. Sri Tantravahi

Day 1 - January 6, 2023

03:00 PM - 04:00 PM PST:         Registration/Networking/Exhibits

04:45 PM – 05:00 PM PST: Opening remarks

05:00 PM – 06:30 PM PST:         Session 1   

Moderator: Dr. Aaron Goodman & Dr. Sri Tantravahi

Tumor board style case-based discussion - Dr. Natasha Edwin, Dr. Eva Medvedova, & Dr. Curtis Lachowiez

 

Day 2 - January 7, 2023

 

07:00 AM - 08:00 AM PST:         Registration/Networking/Exhibits

08:00 AM - 09:30 AM PST:         Session 2

Moderator: Dr. Sri Tantravahi

08:00 AM - 08:30 AM PST:         Myelodysplastic Syndromes - Dr. Luke Fletcher

08:30 AM - 09:00 AM PST:         Myeloproliferative Neoplasms and CML - Dr. Vivian Oehler

09:00 AM - 09:30 AM PST:         Acute Leukemia - Dr. Roland Walter

09:30 AM - 10:00 AM PST:         Break & exhibits

10:00 AM - 11:30 AM PST:         Session 3

Moderator: Dr. Hidong Kim

10:00 AM - 10:30 AM PST:         ITP/TTP, aHUS - Dr. George Rodgers

10:30 AM - 11:00 AM PST:         Clotting Disorders - Dr. Livia Hegerova

11:00 AM - 11:30 AM PST:         Bleeding Disorders - Dr. Joseph Shatzel

11:30 AM - 01:00 PM PST:         Lunch & exhibits

01:00 PM - 02:30 PM PST         Session 4

Moderator: Dr. Craig Okada

01:00 PM - 01:30 PM PST         Chronic Lymphocytic Leukemia - Dr. Mazyar Shadman

01:30 PM - 02:00 PM PST:         Low Grade Lymphomas - Dr. Ryan Lynch

02:00 PM - 02:30 PM PST:         Aggressive Lymphoma - Dr. Stephen Spurgeon

02:30 PM - 03:00 PM PST:         Break & exhibits

03:00 PM - 04:30 PM PST:         Session 5

Moderator: Dr. Bo Wang

03:00 PM - 03:30 PM PST:         Newly Diagnosed Multiple Myeloma - Dr. Shaji Kumar

03:30 PM - 04:00 PM PST:         Cellular Therapy - Dr. Rahul Banerjee

04:00 PM - 04:30 PM PST:         Relapsed Refractory Multiple Myeloma - Dr. Surbhi Sidana

04:30 PM - 04:35 PM PST:         Adjourn

DoubleTree by Hilton
1000 NE Multnomah St
Portland, OR 97232
United States
Book your hotel room here

Hotel reservation

 

Book your room by December 7, 2022, to receive the discounted rate.

 

Parking:

  • Overnight parking is discounted to $10/night.
  • Day parking is discounted to $10/day maximum. 

 

 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Srinivas Tantravahi, MD has a financial relationship (Consulting) with Novartis; a financial relationship (Consulting) with AbbVie; a financial relationship (Research support/Grant Consultant) with Karyopharm Therapeutics.

Speaker/Topic Presenter(s)

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.

Natasha Edwin, MBBS MD

has no relevant financial relationships to disclose at this time.

Luke Fletcher, MD-Hematology and Medical Oncology

has a financial relationship (Professional Services) with Blueprint;.
has a financial relationship (Gift) with Janssen;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with CARIS;.

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.

Livia Hegerova

has a financial relationship (Grant Or Contract) with Agios;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Grant Or Contract) with Rigel;.

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Curtis Lachowiez, M.D.

has no relevant financial relationships to disclose at this time.

Ryan Lynch

has a financial relationship (Grant Or Contract) with Juno Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with TG Therapeutics;.
has a financial relationship (Grant Or Contract) with Cyteir;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Morphosys;.
has a financial relationship (Grant Or Contract) with RAPT;.
has a financial relationship (Grant Or Contract) with SeaGen;.

Eva Medvedova, MD

has no relevant financial relationships to disclose at this time.

Vivian Oehler

has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Pfizer, Inc;.

GEORGE RODGERS, MD, PhD

has a financial relationship (Professional Services) with Dova;.
has a financial relationship (Professional Services) with Argenx;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.

Joseph Shatzel, Dr. Shatzel MD

has a financial relationship (Professional Services) with Aronora;.

Surbhi Sidana, MD

has a financial relationship (Professional Services) with Magenta Therapeutcs, BMS, Janssen, Sanofi, Oncopeptides;.
has a financial relationship (Grant Or Contract) with Magenta Therapeutics, BMS, Allogene, Janssen;.

Stephen Spurgeon, MD

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Acerta;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with BMS/Celgene;.
has a financial relationship (Other) with Schrodinger;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Merck;.

Roland Walter, MD PhD MS

has no relevant financial relationships to disclose at this time.
Moderator(s)

Hidong Kim, MD, PhD

has no relevant financial relationships to disclose at this time.

Craig Okada

has no relevant financial relationships to disclose at this time.

Bo Wang, Bo Wang, MD

has a financial relationship (Independent contractor) with EMD Sorono;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Sanofi Genzyme;.
has a financial relationship (Independent contractor) with Guardant ;.

Commercial Support Acknowledgment

This activity is supported by an independent medical education grant from Apellis Pharmaceuticals, Inc.

Available Credit

  • 7.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 7.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 7.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 7.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 7.50 Contact Hours.

 

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Fellows & residents - $150

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.